PKI - PerkinElmer, Inc.
| Previous close | 98.67 |
| Open | 97.50 |
| Bid | 97.63 x 900 |
| Ask | 97.66 x 800 |
| Day's range | 95.23 - 99.61 |
| 52-week range | 78.35 - 103.00 |
| Volume | 1,335,035 |
| Avg. volume | 585,893 |
| Market cap | 10.869B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 48.00 |
| EPS (TTM) | 2.04 |
| Earnings date | 22 Apr 2020 - 26 Apr 2020 |
| Forward dividend & yield | 0.28 (0.28%) |
| Ex-dividend date | 15 Apr 2020 |
| 1y target est | 102.47 |
- Zacks
PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates
PerkinElmer's (PKI) Q4 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
- Zacks
PerkinElmer (PKI) Tops Q4 Earnings and Revenue Estimates
PerkinElmer (PKI) delivered earnings and revenue surprises of 2.27% and 0.44%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2019
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended December 29, 2019.
- Business Wire
PerkinElmer Board Declares Quarterly Dividend
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on January 23, 2020. This dividend is payable on May 8, 2020 to all shareholders of record at the close of business on April 17, 2020.
- Zacks
PerkinElmer (PKI) to Report Q4 Earnings: What's in the Cards?
Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q4 earnings. However, forex is likely to have remained a woe.
- Zacks
PerkinElmer (PKI) Reports Next Week: Wall Street Expects Earnings Growth
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Waters to Buy Andrew Alliance, Expand Technology Portfolio (Revised)
Waters (WAT) agrees to acquire Andrew Alliance in a bid to expand technology portfolio.
- Simply Wall St.
Are PerkinElmer, Inc. (NYSE:PKI) Investors Paying Above The Intrinsic Value?
How far off is PerkinElmer, Inc. (NYSE:PKI) from its intrinsic value? Using the most recent financial data, we'll take...
- Business Wire
PerkinElmer to Hold Earnings Call on Monday, January 27, 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that on Monday, January 27, 2020, after market close, the Company will release fourth quarter 2019 results. The Company will also host a conference call the same day at 5:00 p.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Jamey Mock, senior vice president and chief financial officer, will host the conference call.
- Zacks
Scientific Instruments Industry Outlook: Prospects Look Good
Scientific Instruments Industry Outlook: Prospects Look Good
- Business Wire
PerkinElmer to Present at J.P. Morgan Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 3:30 p.m. PT at the Westin St. Francis in San Francisco.
- Business Wire
PerkinElmer Launches First FDA-Approved Assay Kit to Screen for Duchenne Muscular Dystrophy in Newborns
PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that its GSP® Neonatal Creatine Kinase –MM (CK-MM) kit has received U.S. Food & Drug Administration (FDA) approval. This solution is the first commercially available assay for screening newborns affected by Duchenne muscular dystrophy (DMD).
- Simply Wall St.
Announcing: PerkinElmer (NYSE:PKI) Stock Increased An Energizing 126% In The Last Five Years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
- Zacks
Here's Why You Should Hold on to PerkinElmer Stock for Now
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
- Simply Wall St.
Should You Be Tempted To Sell PerkinElmer, Inc. (NYSE:PKI) Because Of Its P/E Ratio?
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
- Zacks
PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss
PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
- Zacks
PerkinElmer (PKI) Tops Q3 Earnings Estimates
PerkinElmer (PKI) delivered earnings and revenue surprises of 4.95% and -2.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
PerkinElmer (PKI) to Report Q3 Earnings: What's in Store?
Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q3 earnings. However, forex is likely to have been a dampener.
- Zacks
PerkinElmer (PKI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Should PerkinElmer, Inc. (NYSE:PKI) Focus On Improving This Fundamental Metric?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Zacks
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
- Zacks
Bruker To Buy Freiberg Instruments' Magnettech EPR Business
The Freiberg Instruments' Magnettech EPR business acquisition is expected to boost Bruker's (BRKR) BioSpin business by complementing its existing range of EPR offerings.
- Simply Wall St.
Is It Too Late To Consider Buying PerkinElmer, Inc. (NYSE:PKI)?
PerkinElmer, Inc. (NYSE:PKI), which is in the life sciences business, and is based in United States, saw significant...
- Simply Wall St.
Did PerkinElmer, Inc. (NYSE:PKI) Insiders Sell Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- Zacks
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
